Teva Pharmaceutical Industries launched its generic version of Forest Laboratories’ Lexapro, for the treatment of depression and generalized anxiety disorder. Teva will enjoy six months of marketing exclusivity, as it was the first company to file an Abbreviated New Drug Application with the FDA. Lexapro has been a major revenue generator for Forest Labs with the product generating sales of $1.8 billion in the first nine months of fiscal 2012. View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments